KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

29 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

09 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

03 يناير 2024 18:29:25 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Announces Proposed Public Offering of Common Stock

03 يناير 2024 13:05:39 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

03 يناير 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

11 ديسمبر 2023 03:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

07 نوفمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

06 نوفمبر 2023 05:00:01 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

02 نوفمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

04 أكتوبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

05 سبتمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

07 أغسطس 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

27 يوليو 2023 13:01:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

12 يونيو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

09 يونيو 2023 03:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

07 يونيو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

22 مايو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

11 مايو 2023 13:01:01 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

04 مايو 2023 13:01:00 بحسب Nasdaq GlobeNewswire

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

19 أبريل 2023 05:00:00 بحسب Nasdaq GlobeNewswire